Similarly to the development of biased allosteric modulators for β2AR, which aim to attenuate the side effects associated with the use of long-acting β2AR agonists by avoiding β-arrestin-mediated responses [41], Nbs/NDPs that act as Gαs-biased ligands for β2AR may represent a potential avenue for the development of prospective GPCR-targeted asthma therapeutics. The gene discussed is ADRB2; the disease is asthma.